ADReCS

Pharmaceutical Information

Drug Name	Cisplatin
Drug ID	BADD_D00474
Description	Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
Indications and Usage	For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
Marketing Status	approved
ATC Code	L01XA01
DrugBank ID	DB00515
KEGG ID	D00275
MeSH ID	D002945
PubChem ID	5702198
TTD Drug ID	D0U5HU
NDC Product Code	16729-288; 25021-253; 0143-9505; 68554-0077; 0143-9504; 68001-283; 44567-509; 50711-0001; 44567-510; 63323-103; 0703-5747; 0703-5748; 44567-530; 60505-6277; 68083-163; 44567-511; 49452-2078; 54875-0001; 67184-0010; 68083-162; 70860-206; 49812-0009; 72659-864
UNII	Q20Q21Q62J
Synonyms	Cisplatin \| cis-Diamminedichloroplatinum(II) \| Platinum Diamminodichloride \| Diamminodichloride, Platinum \| cis-Platinum \| cis Platinum \| Dichlorodiammineplatinum \| cis-Diamminedichloroplatinum \| cis Diamminedichloroplatinum \| cis-Dichlorodiammineplatinum(II) \| NSC-119875 \| Platino \| Platinol \| Biocisplatinum \| Platidiam

Chemical Information

Molecular Formula	PtCl2(NH3)2
CAS Registry Number	15663-27-1
SMILES	N.N.Cl[Pt]Cl
Chemical Structure

ADRs Induced by Drug

*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..

ADR Term	ADReCS ID	ADR Frequency (FAERS)	ADR Severity Grade (FAERS)	ADR Severity Grade (CTCAE)
Drop attacks	17.05.02.016; 15.05.04.018	0.000112%		Not Available
Jugular vein thrombosis	24.01.02.007	0.000168%		Not Available
Leiomyosarcoma	16.33.07.001; 15.09.03.016	0.000112%		Not Available
Magnesium deficiency	14.04.02.003	0.000112%		Not Available
Malignant ascites	16.32.03.013; 07.07.01.004	0.000112%		Not Available
Metastases to bone	16.22.02.005; 15.09.03.006	0.000336%		Not Available
Metastases to lymph nodes	16.22.02.006; 01.09.01.015	0.000392%		Not Available
Metastases to pleura	22.05.04.002; 16.22.02.022	0.000112%		Not Available
Myocardial fibrosis	02.04.02.016	0.000112%		Not Available
Neonatal respiratory distress syndrome	22.11.02.010; 18.04.10.003	0.000112%		Not Available
Oesophageal ulcer haemorrhage	24.07.02.051; 07.04.05.007	0.000168%		Not Available
Pancreatic carcinoma metastatic	16.13.10.003; 07.21.09.006	0.000112%		Not Available
Pelvic mass	07.11.01.028; 08.03.05.009; 21.07.04.012	0.000112%		Not Available
Rectal stenosis	07.13.05.003	0.000112%
Squamous cell carcinoma of the oral cavity	16.13.07.006; 07.21.07.009	0.000112%		Not Available
Starvation	14.03.02.025	0.000112%		Not Available
Tonsil cancer	22.08.02.003; 16.19.05.002	0.000358%		Not Available
Ureteric stenosis	20.06.01.010	0.000224%		Not Available
Urinary bladder rupture	20.03.01.024; 12.01.05.007	0.000168%		Not Available
Urogenital fistula	21.10.05.019; 20.08.01.013	0.000392%		Not Available
Wernicke's encephalopathy	17.13.01.013; 14.12.02.013	0.000168%		Not Available
Subclavian vein thrombosis	24.01.02.013	0.000168%		Not Available
Pharyngeal stenosis	22.04.05.019	0.000112%
Xanthogranuloma	01.13.04.005; 15.09.01.009; 16.21.04.005	0.000168%		Not Available
Lymphangiosis carcinomatosa	24.09.02.007; 01.09.01.027; 16.22.02.009	0.000168%		Not Available
Neuroendocrine carcinoma	16.24.01.007; 05.08.01.011	0.000168%		Not Available
Peripheral artery occlusion	24.04.03.022	0.000168%		Not Available
Right ventricular dysfunction	02.04.02.033	0.000112%
Abdominal wall disorder	07.16.05.004	-	-	Not Available
Female genital tract fistula	12.02.14.010; 23.07.04.015; 21.10.05.009; 20.08.01.007; 07.11.05.004	0.000336%		Not Available

The 18th Page First Pre 18 19 20 Next Last Total 20 Pages